BRPI0720178A2 - 2,3-DI-HYDROIMIDAZO [1,2-C] SUBSTITUTED QUINAZOLIN DERIVATIVES USEFUL TO TREAT DIFFERENCES AND ANGIOGENESIS-ASSOCIATED DISEASES - Google Patents

2,3-DI-HYDROIMIDAZO [1,2-C] SUBSTITUTED QUINAZOLIN DERIVATIVES USEFUL TO TREAT DIFFERENCES AND ANGIOGENESIS-ASSOCIATED DISEASES

Info

Publication number: BRPI0720178A2
Authority: BR; Brazil
Prior art keywords: hydroimidazo; angiogenesis; treat; differences; associated diseases
Prior art date: 2006-12-05

Application number

BRPI0720178-8A2A

Other languages

Portuguese (pt)

Inventor

Martin Hentemann

Jill Wood

William Scott

Martin Michels

Ann-Marie Campbell

Ann-Marie Bullion

R Bruce Rowley

Aniko Redman

Original Assignee

Bayer Schering Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-05

Filing date

2007-12-05

Publication date

2013-12-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39492563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0720178(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-12-05 Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag

2013-12-24 Publication of BRPI0720178A2 publication Critical patent/BRPI0720178A2/en

2019-04-09 Publication of BRPI0720178B1 publication Critical patent/BRPI0720178B1/en

2021-05-25 Publication of BRPI0720178B8 publication Critical patent/BRPI0720178B8/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Agronomy & Crop Science (AREA)
Pest Control & Pesticides (AREA)
Environmental Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Dentistry (AREA)
Plant Pathology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)

BRPI0720178A 2006-12-05 2007-12-05 substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis, and pharmaceutical compositions BRPI0720178B8 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US87309006P	2006-12-05	2006-12-05
US60/873,090		2006-12-05
PCT/US2007/024985 WO2008070150A1 (en)	2006-12-05	2007-12-05	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Publications (3)

Publication Number	Publication Date
BRPI0720178A2 true BRPI0720178A2 (en)	2013-12-24
BRPI0720178B1 BRPI0720178B1 (en)	2019-04-09
BRPI0720178B8 BRPI0720178B8 (en)	2021-05-25

Family

ID=39492563

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0720178A BRPI0720178B8 (en)	2006-12-05	2007-12-05	substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis, and pharmaceutical compositions

Country Status (41)

Country	Link
US (3)	US8466283B2 (en)
EP (1)	EP2096919B1 (en)
JP (1)	JP5326092B2 (en)
KR (1)	KR101501785B1 (en)
CN (4)	CN108774232B (en)
AR (1)	AR064106A1 (en)
AU (1)	AU2007328008B2 (en)
BR (1)	BRPI0720178B8 (en)
CA (1)	CA2671614C (en)
CL (1)	CL2007003508A1 (en)
CO (1)	CO6220908A2 (en)
CR (1)	CR10838A (en)
CU (1)	CU23796B7 (en)
DK (1)	DK2096919T3 (en)
DO (1)	DOP2009000135A (en)
EA (1)	EA018839B1 (en)
EC (1)	ECSP099387A (en)
ES (1)	ES2572189T3 (en)
GT (1)	GT200900154A (en)
HN (1)	HN2009001131A (en)
HU (1)	HUE028773T2 (en)
IL (1)	IL198273A (en)
JO (1)	JO3147B1 (en)
MA (1)	MA31283B1 (en)
MX (1)	MX2009006001A (en)
MY (1)	MY157944A (en)
NO (1)	NO342348B1 (en)
NZ (1)	NZ577342A (en)
PA (1)	PA8759601A1 (en)
PE (1)	PE20081444A1 (en)
PL (1)	PL2096919T3 (en)
RS (1)	RS56045B1 (en)
SG (1)	SG177170A1 (en)
SI (1)	SI2096919T1 (en)
SV (1)	SV2009003288A (en)
TN (1)	TN2009000137A1 (en)
TW (1)	TWI406662B (en)
UA (1)	UA96965C2 (en)
UY (1)	UY30761A1 (en)
WO (1)	WO2008070150A1 (en)
ZA (1)	ZA200904691B (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2713388C (en) *	2008-01-14	2016-03-29	William Scott	Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2168583A1 (en) *	2008-09-24	2010-03-31	Bayer Schering Pharma Aktiengesellschaft	Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2168582A1 (en)	2008-09-24	2010-03-31	Bayer Schering Pharma Aktiengesellschaft	Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
US8791131B2 (en) *	2008-09-30	2014-07-29	Pfizer Inc.	Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
EP2184276A1 (en)	2008-11-07	2010-05-12	Universite Paul Cezanne Aix-Marseille Iii	Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors
US8648190B2 (en)	2009-01-16	2014-02-11	Daiso Co., Ltd.	Process for producing 2-hydroxymethylmorpholine salt
WO2011107494A1 (en)	2010-03-03	2011-09-09	Sanofi	Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
EA201201414A8 (en) *	2010-04-16	2013-12-30	Байер Интеллектчуал Проперти Гмбх	COMBINATIONS CONTAINING SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-c] HINAZOLINES
EP2582709B1 (en)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN103298469A (en)	2010-08-31	2013-09-11	首尔大学校产学协力财团	Use of the fetal reprogramming of a PPAR delta agonist
US9675616B2 (en)	2010-11-11	2017-06-13	Bayer Intellectual Property Gmbh	Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines
CN103339133B (en) *	2010-11-11	2016-06-15	拜耳知识产权有限责任公司	2 of alkoxyl replacement, 3-glyoxalidine is [1,2-c] quinazoline also
UA113280C2 (en) *	2010-11-11	2017-01-10		AMINOSPIRT-SUBSTITUTED Derivatives of 2,3-Dihydroimimidase $ 1,2-c] QINAZOLINE, SUITABLE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS, DISEASES AND DISEASES
EP2508525A1 (en) *	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (en)	2011-04-05	2021-01-31	Bayer Ip Gmbh	Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6427097B2 (en)	2012-06-15	2018-11-21	ザブリガムアンドウィメンズホスピタルインコーポレイテッドＴｈｅＢｒｉｇｈａｍａｎｄＷｏｍｅｎ’ｓＨｏｓｐｉｔａｌ，Ｉｎｃ．	Compositions for treating cancer and methods for producing said compositions
WO2014068070A1 (en)	2012-10-31	2014-05-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preventing antiphospholipid syndrome (aps)
KR102185175B1 (en) *	2012-11-02	2020-12-02	티지 쎄라퓨틱스, 인코포레이티드	Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
CN103214489B (en) *	2013-02-25	2016-10-26	中国人民解放军第二军医大学	One class Mutiple Targets inhibitors of kinases with anti-tumor activity and preparation method thereof
AP2015008750A0 (en)	2013-04-08	2015-09-30	Bayer Pharma AG	Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
CN104557955B (en) *	2013-10-23	2017-05-03	上海汇伦生命科技有限公司	Tricyclic compound as PI3K/mTOR inhibitor as well as preparation method and application of tricyclic compound
WO2015081127A2 (en) *	2013-11-26	2015-06-04	Gilead Sciences, Inc.	Therapies for treating myeloproliferative disorders
WO2015082378A1 (en)	2013-12-03	2015-06-11	Bayer Pharma Aktiengesellschaft	Combination of pi3k-inhibitors
CN105934256B (en) *	2013-12-03	2019-12-27	拜耳制药股份公司	PI3K inhibitor combination
TWI533869B (en)	2014-03-11	2016-05-21	國立中央大學	Indication of anthra(2,1-c)(1,2,5)thiadiazole-6,11-dione compound in alleviating pain
TWI533871B (en)	2014-03-11	2016-05-21	國立中央大學	Indication of naphtho(2,3-f)quinoxaline-7,12-dione compound in alleviating pain
FR3018813B1 (en) *	2014-03-18	2016-04-15	Maco Pharma Sa	PROCESS FOR SYNTHESIZING A PSORALENE DERIVATIVE
WO2016059220A1 (en)	2014-10-16	2016-04-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Tcr-activating agents for use in the treatment of t-all
EP3018131A1 (en) *	2014-11-07	2016-05-11	Bayer Pharma Aktiengesellschaft	Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) *	2014-11-07	2016-05-11	Bayer Pharma Aktiengesellschaft	Synthesis of copanlisib and its dihydrochloride salt
EA201791974A1 (en) *	2015-03-09	2018-05-31	Байер Фарма Акциенгезельшафт	COMBINATIONS CONTAINING SUBSTITUTE 2,3-DIHYDROIMIDAZO [1,2-С] HINAZOLIN
WO2016142313A1 (en) *	2015-03-09	2016-09-15	Bayer Pharma Aktiengesellschaft	Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
FR3033499A1 (en) *	2015-03-11	2016-09-16	Centre Leon-Berard	COMPOSITION FOR THE TREATMENT OF PANCREATIC NEUROENDOCRINE TUMORS
CN111909173B (en) *	2015-07-02	2025-03-04	豪夫迈·罗氏有限公司	Benzoxazepine oxazolidinone compounds and methods of use thereof
CN105130998B (en) *	2015-09-25	2017-07-28	苏州立新制药有限公司	Ku Pannixi preparation method
CN105130997B (en) *	2015-09-25	2017-12-05	苏州明锐医药科技有限公司	A kind of Ku Pannixi preparation method
WO2017153220A1 (en)	2016-03-08	2017-09-14	Bayer Pharma Aktiengesellschaft	2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
EP3219329A1 (en)	2016-03-17	2017-09-20	Bayer Pharma Aktiengesellschaft	Combinations of copanlisib
US10925869B2 (en) *	2016-05-26	2021-02-23	University of Pittsburgh—of the Commonwealth System of Higher Education	Compositions and methods for treating pulmonary vascular disease
CN108368117B (en) *	2016-06-08	2021-03-02	深圳市塔吉瑞生物医药有限公司	A kind of substituted imidazoquinazoline compound and pharmaceutical composition thereof
WO2018054782A1 (en)	2016-09-23	2018-03-29	Bayer Pharma Aktiengesellschaft	Combination of pi3k-inhibitors
CN106177918A (en) *	2016-09-30	2016-12-07	广州赛莱拉干细胞科技股份有限公司	A kind of mesenchymal stem cell injection and its preparation method and application
AU2017376766A1 (en)	2016-12-14	2019-06-06	Tva (Abc), Llc	HSP90-targeting conjugates and formulations thereof
CA3054249A1 (en)	2017-02-24	2018-08-30	Bayer Pharma Aktiengesellschaft	Combinations of copanlisib with anti-pd-1 antibody
WO2018215282A1 (en)	2017-05-26	2018-11-29	Bayer Pharma Aktiengesellschaft	Combination of bub1 and pi3k inhibitors
CA3068324A1 (en)	2017-06-28	2019-01-03	Bayer Consumer Care Ag	Combination of a pi3k-inhibitor with an androgen receptor antagonist
WO2019010491A1 (en) *	2017-07-07	2019-01-10	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Drug combinations for protecting against neuronal cell death
JP6916562B2 (en) *	2017-08-11	2021-08-11	テリジーンリミテッドＴｅｌｉｇｅｎｅＬｔｄ．	Compounds, pharmaceutically acceptable salts thereof, solvates, stereoisomers and tautomers, and drug compositions, hyperproliferative disorder therapeutic agents, hyperproliferative disorder prophylaxis agents, drugs, cancer therapeutic agents, cancer Prophylactic agents and kinase signaling regulators
WO2019048527A1 (en)	2017-09-08	2019-03-14	Bayer Pharma Aktiengesellschaft	Formulations of copanlisib
EP3498266A1 (en)	2017-12-15	2019-06-19	Bayer Consumer Care AG	Formulations of copanlisib
WO2019105734A1 (en)	2017-11-28	2019-06-06	Bayer Consumer Care Ag	Combinations of copanlisib
WO2019105835A1 (en)	2017-11-29	2019-06-06	Bayer Consumer Care Ag	Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en)	2018-04-11	2019-10-17	Bayer Aktiengesellschaft	Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
CN108383849B (en) *	2018-04-26	2020-11-06	浙江大学	Imidazoquinazoline Derivatives and Their Application in Anti-tumor and Anti-inflammatory
CN108841318A (en) *	2018-07-12	2018-11-20	中国科学院海洋研究所	A kind of selfreparing aquagel anticorrosive paint and its synthetic method
US20210187134A1 (en)	2018-08-28	2021-06-24	Bayer As	Combination of pi3k-inhibitors and targeted thorium conjugates
EP3866805A1 (en)	2018-10-16	2021-08-25	Bayer Aktiengesellschaft	Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
CN109516961B (en)	2018-12-25	2021-01-01	浙江大学	Aminoquinazolinone and aminoisoquinolinone derivatives and uses thereof
WO2020164997A1 (en)	2019-02-12	2020-08-20	Bayer Aktiengesellschaft	Combination of pi3k-inhibitors
US12653785B2 (en)	2020-05-21	2026-06-16	University of Pittsburgh—of the Commonwealth System of Higher Education	Compositions and methods for administering a YAP1/WWRT1 inhibiting composition and a GLS1 inhibiting composition
WO2023101359A1 (en) *	2021-11-30	2023-06-08	광주과학기술원	Composition comprising pip4k2c inhibitor as active ingredient for treatment of cancer
WO2023139125A1 (en)	2022-01-18	2023-07-27	Synthon B.V.	Improved process for preparation of copanlisib
WO2023218032A1 (en)	2022-05-13	2023-11-16	Synthon B.V.	Solid forms of copanlisib salts

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3644354A (en)	1968-09-16	1972-02-22	Sandoz Ag	5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4146718A (en) *	1978-04-10	1979-03-27	Bristol-Myers Company	Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
EP1277754B8 (en) *	2000-04-27	2005-09-28	Astellas Pharma Inc.	Imidazopyridine derivatives
US6608053B2 (en) *	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
PA8578001A1 (en) *	2002-08-07	2004-05-07	Warner Lambert Co	THERAPEUTIC COMBINATIONS OF ERB B QUINASA INHIBITORS AND ANTINEOPLASIC THERAPIES
WO2004029055A1 (en) *	2002-09-30	2004-04-08	Bayer Pharmaceuticals Corporation	Fused azole-pyrimidine derivatives
JP2007501863A (en) *	2003-06-12	2007-02-01	メルク　エンド　カムパニー　インコーポレーテッド	Mitotic kinesin inhibitor
AT412873B (en)	2004-02-20	2005-08-25	Aop Orphan Pharmaceuticals Ag	Preparation of anagrelide hydrochloride, useful for thrombocyte suppression, using 2,3-dichlorobenzaldehyde as starting material, avoids use of toxic reagents
WO2007143483A2 (en)	2006-06-01	2007-12-13	Smithkline Beecham Corporation	Combination of pazopanib and lapatinib for treating cancer
WO2008002039A1 (en)	2006-06-28	2008-01-03	Hanmi Pharm. Co., Ltd.	Quinazoline derivatives for inhibiting the growth of cancer cell
EP2508525A1 (en)	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

2007
- 2007-12-03 AR ARP070105390A patent/AR064106A1/en active IP Right Grant
- 2007-12-04 PA PA20078759601A patent/PA8759601A1/en unknown
- 2007-12-04 PE PE2007001709A patent/PE20081444A1/en active IP Right Grant
- 2007-12-04 UY UY30761A patent/UY30761A1/en not_active Application Discontinuation
- 2007-12-04 TW TW096145999A patent/TWI406662B/en not_active IP Right Cessation
- 2007-12-04 JO JOP/2007/0517A patent/JO3147B1/en active
- 2007-12-05 RS RS20170561A patent/RS56045B1/en unknown
- 2007-12-05 EP EP07862580.3A patent/EP2096919B1/en active Active
- 2007-12-05 JP JP2009540293A patent/JP5326092B2/en not_active Expired - Fee Related
- 2007-12-05 CA CA2671614A patent/CA2671614C/en active Active
- 2007-12-05 CN CN201810535933.9A patent/CN108774232B/en active Active
- 2007-12-05 CN CN201510632842.3A patent/CN105254634B/en not_active Expired - Fee Related
- 2007-12-05 PL PL07862580T patent/PL2096919T3/en unknown
- 2007-12-05 US US12/517,875 patent/US8466283B2/en not_active Ceased
- 2007-12-05 MX MX2009006001A patent/MX2009006001A/en active IP Right Grant
- 2007-12-05 US US15/398,916 patent/USRE46856E1/en not_active Expired - Fee Related
- 2007-12-05 AU AU2007328008A patent/AU2007328008B2/en not_active Ceased
- 2007-12-05 HU HUE07862580A patent/HUE028773T2/en unknown
- 2007-12-05 EA EA200900733A patent/EA018839B1/en not_active IP Right Cessation
- 2007-12-05 CL CL200703508A patent/CL2007003508A1/en unknown
- 2007-12-05 KR KR1020097011551A patent/KR101501785B1/en not_active Expired - Fee Related
- 2007-12-05 CN CN200780044849.7A patent/CN101631464B/en active Active
- 2007-12-05 SI SI200731771A patent/SI2096919T1/en unknown
- 2007-12-05 CN CN202211453281.7A patent/CN115724847A/en active Pending
- 2007-12-05 DK DK07862580.3T patent/DK2096919T3/en active
- 2007-12-05 NZ NZ577342A patent/NZ577342A/en not_active IP Right Cessation
- 2007-12-05 BR BRPI0720178A patent/BRPI0720178B8/en not_active IP Right Cessation
- 2007-12-05 SG SG2011088887A patent/SG177170A1/en unknown
- 2007-12-05 WO PCT/US2007/024985 patent/WO2008070150A1/en not_active Ceased
- 2007-12-05 UA UAA200906701A patent/UA96965C2/en unknown
- 2007-12-05 ES ES07862580T patent/ES2572189T3/en active Active
- 2007-12-05 MY MYPI20092044A patent/MY157944A/en unknown
2009
- 2009-04-13 TN TNP2009000137A patent/TN2009000137A1/en unknown
- 2009-04-21 IL IL198273A patent/IL198273A/en active IP Right Grant
- 2009-06-04 EC EC2009009387A patent/ECSP099387A/en unknown
- 2009-06-04 CO CO09057915A patent/CO6220908A2/en active IP Right Grant
- 2009-06-04 HN HN2009001131A patent/HN2009001131A/en unknown
- 2009-06-05 SV SV2009003288A patent/SV2009003288A/en unknown
- 2009-06-05 CR CR10838A patent/CR10838A/en unknown
- 2009-06-05 CU CU20090103A patent/CU23796B7/en active IP Right Grant
- 2009-06-05 DO DO2009000135A patent/DOP2009000135A/en unknown
- 2009-06-05 GT GT200900154A patent/GT200900154A/en unknown
- 2009-06-29 MA MA32057A patent/MA31283B1/en unknown
- 2009-07-03 NO NO20092529A patent/NO342348B1/en unknown
- 2009-07-03 ZA ZA200904691A patent/ZA200904691B/en unknown
2013
- 2013-06-03 US US13/908,566 patent/US20130261113A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1217953A1 (en)	2017-01-27
CN105254634A (en)	2016-01-20
ES2572189T3 (en)	2016-05-30
USRE46856E1 (en)	2018-05-22
AU2007328008B2 (en)	2014-03-13
BRPI0720178B8 (en)	2021-05-25
WO2008070150A1 (en)	2008-06-12
CA2671614C (en)	2016-01-26
MY157944A (en)	2016-08-30
CN108774232B (en)	2022-08-09
NO20092529L (en)	2009-08-27
NO342348B1 (en)	2018-05-07
EP2096919A4 (en)	2010-11-17
EP2096919B1 (en)	2016-03-02
SI2096919T1 (en)	2016-06-30
TW200840582A (en)	2008-10-16
CU20090103A7 (en)	2011-12-28
PA8759601A1 (en)	2009-02-09
IL198273A0 (en)	2009-12-24
PL2096919T3 (en)	2016-08-31
JP2010511718A (en)	2010-04-15
KR20090096440A (en)	2009-09-10
IL198273A (en)	2015-07-30
CN105254634B (en)	2022-05-27
TWI406662B (en)	2013-09-01
PE20081444A1 (en)	2008-11-29
HUE028773T2 (en)	2017-01-30
US8466283B2 (en)	2013-06-18
CO6220908A2 (en)	2010-11-19
CL2007003508A1 (en)	2008-07-04
UA96965C2 (en)	2011-12-26
MX2009006001A (en)	2009-06-16
AR064106A1 (en)	2009-03-11
US20110083984A1 (en)	2011-04-14
BRPI0720178B1 (en)	2019-04-09
CU23796B7 (en)	2012-03-15
CA2671614A1 (en)	2008-06-12
CR10838A (en)	2009-11-05
UY30761A1 (en)	2008-07-03
TN2009000137A1 (en)	2010-10-18
US20130261113A1 (en)	2013-10-03
DK2096919T3 (en)	2016-05-17
JP5326092B2 (en)	2013-10-30
RS56045B1 (en)	2017-09-29
DOP2009000135A (en)	2009-06-30
EA018839B1 (en)	2013-11-29
HN2009001131A (en)	2012-02-06
CN108774232A (en)	2018-11-09
JO3147B1 (en)	2017-09-20
MA31283B1 (en)	2010-04-01
EA200900733A1 (en)	2009-12-30
GT200900154A (en)	2012-01-17
EP2096919A1 (en)	2009-09-09
SG177170A1 (en)	2012-01-30
CN101631464A (en)	2010-01-20
ZA200904691B (en)	2010-09-29
ECSP099387A (en)	2009-11-30
SV2009003288A (en)	2009-10-02
AU2007328008A1 (en)	2008-06-12
CN101631464B (en)	2022-12-06
NZ577342A (en)	2012-01-12
KR101501785B1 (en)	2015-03-11
CN115724847A (en)	2023-03-03

Legal Events

Date	Code	Title	Description
2014-04-15	B25D	Requested change of name of applicant approved	Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)
2014-05-06	B25A	Requested transfer of rights approved	Owner name: BAYER INTELLECTUAL PROPERTY GMBH. (DE)
2018-03-20	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2018-03-20	B65X	Notification of requirement for priority examination of patent application
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-02	B65Y	Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
2018-11-06	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2018-11-13	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-02-26	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-04-09	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2024-04-02	B25G	Requested change of headquarter approved	Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)
2025-10-07	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 18A ANUIDADE.
2026-01-27	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2857 DE 07-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
SMT201500206B (en)	2015-10-30	Spiro-oxindolic compounds and their use as therapeutic agents
ATE467633T1 (en)	2010-05-15	2-ARYL-6-PHENYLIMIDAZOÄ1,2-AÜPYRIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE
BRPI0813725A2 (en)	2014-12-30	METHODS AND COMPOSITIONS FOR DISEASE TREATMENT
HUS1600048I1 (en)	2017-01-30	Preparation for the treatment of Fabry disease
SI3424932T1 (en)	2021-08-31	Boronophthalides for therapeutic use
ZA200904691B (en)	2010-09-29	Substituted 2,3-dihydroimidazo[1,2-C]Quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
SI2084151T1 (en)	2013-10-30	Substituted dihydropyrazolones for the treatment of cardiovascular and hematologic diseases
ECSP088904A (en)	2008-12-30	ARILIMIDAZOLONAS AND ARILTRIAZOLONAS REPLACED AS INHIBITORS OF VASOPRESINE RECEPTORS
BRPI0812755A2 (en)	2014-09-30	FENIL ALKINILA DERIVATIVE COMPOUNDS TO TREAT DISEASES, AND Ophthalmic Disorders
BRPI0909954A2 (en)	2015-11-03	"diazacarbazoles and methods of use"
BR112012001344A2 (en)	2016-03-15	17hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, their production method and their use in the treatment of diseases
CL2007002837A1 (en)	2008-07-18	USE OF PHENITOIN TO TREAT ORAL MUCOSITIS.
PL1904056T3 (en)	2009-09-30	The use of macrolide to restore corneal sensation
BRPI0718041A2 (en)	2015-05-12	Angiotensin II Receptor Antagonist for the Prevention or Treatment of Systemic Diseases in Cats
SI2176252T1 (en)	2014-12-31	2, 3-dihydrobenzoš1, 4ćdioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases
PL2049127T3 (en)	2015-03-31	N-methanocarba derivatives to treat cardiac diseases
PT2056804E (en)	2014-07-11	USE OF 2,5-DIHYDROXYBENZEN DERIVATIVES FOR THE TREATMENT OF EYE DISEASES
BRPI0908049A2 (en)	2015-08-11	Use of pririmidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that are directed to egfr family members
DK1993589T3 (en)	2014-01-06	Treatments for neurological diseases
EP2049899A4 (en)	2010-04-14	Methods to prevent and treat diseases
EP2034834A4 (en)	2010-03-24	PRODRUGS OF 5-AMINO-3- (3'-DEOXY-BETA-D-RIBOFURANNOSYL) -THIAZOLO [4,5-D] PYRIMIDIN-2,7-DIONE
BRPI0822223A2 (en)	2015-06-23	Imidazo [1,2-alpha] pyridine-2-carboxamides derivatives, their preparation and their therapeutic application
BRPI0818121A2 (en)	2015-11-17	diespiro 1,2,4-trioxolane and its methods of manufacture and use
ZA200810565B (en)	2009-11-25	Pyrimidine derivatives and their use as pesticides
BRPI0814177A2 (en)	2015-01-20	1-OXO-1,2-DI-HYDROISOQUINOLEIN-5-CARBOXAMIDES AND 4-OXO-3,4-DI-HYDROQUINAZOLINE-8-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION